Mansour Marc R, Sulis Maria L, Duke Veronique, Foroni Letizia, Jenkinson Sarah, Koo Kenneth, Allen Christopher G, Gale Rosemary E, Buck Georgina, Richards Sue, Paietta Elisabeth, Rowe Jacob M, Tallman Martin S, Goldstone Anthony H, Ferrando Adolfo A, Linch David C
Department of Haematology, University College London, UCL Cancer Institute, WC1E 6BT, United Kingdom.
J Clin Oncol. 2009 Sep 10;27(26):4352-6. doi: 10.1200/JCO.2009.22.0996. Epub 2009 Jul 27.
Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome. Their prognostic significance in adult T-ALL is unclear. We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol.
NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome.
NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count. NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations (P = .02), and NOTCH1 proline, glutamic acid, serine, threonine (PEST) rich domain and FBXW7 mutations were mutually exclusive. There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated (MUT) groups. Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6). Analysis by each marker individually was not significantly predictive of outcome (NOTCH1 MUT v WT, EFS 49% v 34%, P = .20; FBXW7 MUT v WT, EFS 53% v 41%, P.72).
NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies.
NOTCH1和/或FBXW7突变激活Notch信号通路是T细胞急性淋巴细胞白血病(T-ALL)最常见的分子事件之一,在儿童疾病中,这一事件预示着良好的预后。其在成人T-ALL中的预后意义尚不清楚。我们试图根据接受英国急性淋巴细胞白血病XII(UKALLXII)/东部肿瘤协作组(ECOG)E2993方案治疗的成人T-ALL患者的突变状态评估其预后。
采用变性高效液相色谱和测序相结合的方法对88例接受UKALLXII/ECOG E2993方案治疗的成人T-ALL患者进行NOTCH1和FBXW7筛查,并与临床特征和预后进行比较。
NOTCH1和FBXW7突变很常见(分别为60%和18%),且与年龄或白细胞计数无关。NOTCH1异二聚化结构域突变与FBXW7突变相关(P = 0.02),NOTCH1富含脯氨酸、谷氨酸、丝氨酸、苏氨酸(PEST)的结构域突变与FBXW7突变相互排斥。NOTCH1和FBXW7突变(MUT)组中高危和标准风险患者数量相等。两种标志物均为野生型(WT)的患者无事件生存期(EFS)有较差的趋势(MUT组与WT组,51%对27%,P = 0.10;风险比,0.6)。单独分析每个标志物对预后均无显著预测价值(NOTCH1 MUT组与WT组,EFS 49%对34%,P = 0.20;FBXW7 MUT组与WT组,EFS 53%对41%,P = 0.72)。
NOTCH1和FBXW7突变阳性患者的预后不够理想,因此在未来研究中不值得采用个体化治疗方法。